Welcome to our dedicated page for Dianthus Therapeutics /DE/ SEC filings (Ticker: DNTH), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on Dianthus Therapeutics /DE/'s stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into Dianthus Therapeutics /DE/'s regulatory disclosures and financial reporting.
Dianthus Therapeutics entered a License and Collaboration Agreement with Nanjing Leads Biolabs, securing exclusive rights outside Greater China to develop and commercialize DNTH212 (LBL-047), an investigational bifunctional fusion protein that targets pDC BDCA2 to reduce Type 1 interferon while inhibiting BAFF/APRIL to suppress B-cell function.
Consideration includes up to $38 million, comprised of $30 million in upfront and near‑term milestone payments and an additional $8 million milestone payable at the initiation of a Dianthus‑led Phase 1 study, at the company’s election in cash or stock. Leads may earn up to $962 million in development, regulatory, and sales milestones across five indications, plus tiered royalties from mid‑single digits up to low double‑digit on ex‑Greater China net sales.
A joint steering committee will oversee DNTH212; Leads can participate in global studies and enroll patients in Greater China and will cover certain related costs. The parties agreed to non‑competition outside Greater China. Dianthus reported approximately $555 million in cash, cash equivalents, and investments as of September 30, 2025, and $525 million pro forma after deducting near‑term and upfront payments.
Marino Garcia, who serves as CEO and President and a director of Dianthus Therapeutics, Inc. (DNTH), was awarded a stock option on 09/30/2025 to purchase 120,000 shares of the company's common stock at an exercise price of $39.35 per share. The option is exercisable through 09/30/2035 and will vest in equal monthly installments over the four years following the grant, subject to the reporting person’s continued service. After the grant the reporting person beneficially owns 120,000 shares underlying the option on a direct basis.
Ryan Savitz, Chief Financial Officer and Chief Business Officer of Dianthus Therapeutics, Inc. (DNTH), was granted a stock option on September 23, 2025 to purchase 60,000 shares of common stock at an exercise price of $37.87 per share. The option vests in equal monthly installments over four years beginning on the grant date and expires on September 23, 2035. The reporting on Form 4 was signed by an attorney-in-fact on September 25, 2025. The award is reported as a direct beneficial ownership of 60,000 underlying shares immediately following the transaction.
Dianthus Therapeutics insider grant: Simrat Randhawa, Chief Medical Officer of Dianthus Therapeutics (DNTH), was granted a stock option on 09/23/2025 to purchase 60,000 shares of common stock. The option has an exercise/conversion price of $37.87 per share and an exercise/expiration date of 09/23/2035. The award vests in equal monthly installments over four years starting 09/23/2025, subject to continued service. The filing reports the holdings as 60,000 shares held directly following the transaction and is signed on behalf of the reporting person by an attorney-in-fact.
Fairmount Funds Management and affiliated entities reported beneficial voting and dispositive power over 4,052,052 shares of Dianthus Therapeutics, Inc. (DNTH), representing 9.9% of the outstanding common stock based on 40,561,085 shares as of September 11, 2025. The position includes 3,307,191 shares of common stock and pre-funded warrants exercisable for up to 744,861 shares subject to a 9.99% beneficial ownership limitation. On September 11, 2025, Fairmount Healthcare Fund II L.P. purchased 600,000 shares in the company’s underwritten public offering at $33.00 per share for aggregate consideration of $19,800,000. Tomas Kiselak resigned from the Board on March 4, 2025, and the Reporting Persons state they currently have no present plans to effect corporate actions, while reserving the right to review or change that position in the future.
Insider transactions at Dianthus Therapeutics (DNTH): Chief Financial & Business Officer Ryan Savitz executed and sold shares under a Rule 10b5-1 plan on 09/09/2025. He exercised a stock option to buy 20,000 shares at a $8.44 exercise price and simultaneously sold 20,000 shares at $35 per share. After these transactions, the reporting person beneficially owns 104,766 shares of common stock. The option award underlying the exercise vests over time, with 25% vested on 06/02/2023 and the remainder vesting monthly over the following three years. The filing was signed by an attorney-in-fact on 09/11/2025.
Dianthus Therapeutics entered into an underwriting agreement to sell 6,487,879 shares of common stock at $33.00 per share and, in lieu of common stock to certain investors, pre-funded warrants to purchase 1,112,121 shares at $32.999 per pre-funded warrant. The company also granted the underwriters an option to buy up to an additional 1,140,000 shares of common stock at the public offering price, less underwriting discounts and commissions, and this option has been exercised in full. Net proceeds from this equity and pre-funded warrant offering, including the exercised option, are expected to be approximately $270.0 million after underwriting discounts, commissions, and estimated expenses. The securities are being issued off an effective shelf registration statement, with the offering expected to close on September 11, 2025.
Dianthus Therapeutics, Inc. (DNTH) Form 144 notifies the SEC of a proposed sale of 20,000 shares of common stock acquired on 09/09/2025 via exercise of stock options from the issuer. The filer lists Morgan Stanley Smith Barney LLC Executive Financial Services as the broker, with an approximate aggregate market value of $636,000.00 and that the company has 32,188,345 shares outstanding. The notice indicates the shares were to be paid for in cash on the same acquisition date and that there were no reported sales by the seller in the prior three months. The filing includes the standard representation that the seller is not aware of undisclosed material adverse information.
Dianthus Therapeutics is offering shares of common stock and pre-funded warrants exercisable for common stock. Each pre-funded warrant has an exercise price of $0.001 per share and is exercisable any time after issuance subject to ownership limits (holders may elect limits up to 19.99% with prior notice). The company does not intend to list the pre-funded warrants, which may limit liquidity. The prospectus states the company will use net proceeds to advance preclinical and clinical development and for working capital. The public offering price per share and certain total dollar amounts are redacted in the provided text. The company’s common stock trades on Nasdaq under DNTH, with a last reported sale price of $26.50 on September 5, 2025. The prospectus warns new investors will incur immediate dilution (amounts redacted) and describes cashless exercise mechanics and transfer and tax considerations for U.S. and Non-U.S. holders.
Dianthus Therapeutics announced positive top-line results from its Phase 2 MaGic trial of claseprubart (DNTH103) in adults with acetylcholine receptor antibody positive generalized myasthenia gravis. The study evaluated both safety and efficacy of DNTH103 in this autoimmune neuromuscular disease population.
The company is hosting a conference call and webcast on September 8, 2025, at 8:00 a.m. Eastern Time to discuss the data. A detailed press release and an investor data presentation have been made available as exhibits and on the company’s website, providing more insight into the trial outcomes.